V

Viatris

Global pharma selling generics and biosimilars

Senior Director Nonclinical Development

Full-Time
$151k - $314k
Expert
Bachelor's, PharmD, PhD, Doctor of Veterinary Medicine (DVM)
Remote in USA
RemotePeriodic travel may be required.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Minimum of a Bachelor's degree or equivalent and 15 years of experience; a combination of experience and/or education will be considered.
  • Possess expert knowledge of pharmaceutical drug development requirements for regulatory submissions.
  • Possess expert in-depth knowledge of product development, analytical sciences, clinical operations, Good Manufacturing Practice, Good Laboratory Practice, Good Clinical Practice, and global regulatory processes for brand/specialty and generic product approval.
  • Provide guidance to Research and Development, Regulatory, and Business Development project teams; understand technical problems and recommend solutions.
  • Read and interpret comprehensive and intricate research documents; write scientific reports and technical correspondence.
  • Work with executives and present abstract concepts to senior organizational audiences and external groups.
  • Solve complex problems using independent judgment, analysis, inference, and deductive reasoning.
  • Proficiency in speaking, comprehending, reading, and writing English is required.
Responsibilities
  • Direct all aspects of nonclinical development, including staffing, supervision, work direction, goal setting, and prioritization.
  • Oversee nonclinical regulatory strategy, experiment design, data interpretation, and oral and written presentation of results.
  • Oversee review and approval of preclinical protocols and final reports and ensure data quality and integrity at preclinical sites.
  • Communicate preclinical findings to project teams, senior management, regulators, and external partners.
  • Oversee research and preparation of regulatory study documents for new and complex product development, including Investigational New Drug and New Drug Application preclinical sections.
  • Represent Viatris and Global Pharmacology and Toxicology in meetings with regulatory agencies.
  • Provide technical support to company departments on pharmacology and toxicology.
  • Perform and review toxicological risk assessments for health-based exposure limits, including acceptable daily exposures, permitted daily exposures, acceptable daily intakes, and occupational exposure limits.
  • Assist with departmental budget development and adherence.
  • Review relevant Standard Operating Procedures for comprehension.
  • Directly supervise employees, including interviewing, hiring, training, planning and assigning work, appraising performance, rewarding and disciplining employees, and resolving complaints and problems.
Desired Qualifications
  • Doctor of Veterinary Medicine, Doctor of Philosophy in a biomedical discipline, or Doctor of Pharmacy degree, with 10 years of relevant pharmaceutical experience.

About the company

Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.

Company Size

10,001+

Company Stage

IPO

Headquarters

Canonsburg, Pennsylvania

Founded

1961

Get referred to Viatris

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue rose 5% to $3.8 billion, and guidance increased.
  • Debt fell after $900 million repayment, reducing gross leverage to 2.9x.
  • Tyrvaya divestiture, Gwyn Lo, and meloxicam NDA support a higher-value portfolio shift.

What critics are saying

  • Nashik fire and FDA Form 483 disruptions cut second-half 2026 revenue by $100-$150 million.
  • Greater China procurement changes pressure hospital volumes, squeezing one of Viatris's fastest growth engines.
  • Generic pricing MDL and ongoing patent fights in Japan keep legal overhangs persistent.

What makes Viatris unique

  • Viatris pairs 165-country reach with complex generics, branded drugs, and biosimilars.
  • Japan approved WAKIX on September 16, 2026, expanding first-in-class sleep medicine reach.
  • FDA approved Gwyn Lo on July 29, 2026, adding a differentiated women’s health product.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Life Insurance

401(k) Retirement Plan

401(k) Company Match

Wellness Program

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

18%

1 year growth

18%

2 year growth

18%
South Jordan Journal
Oct 8th, 2026
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

The South Jordan Journal is the local newspaper covering news and events in the City of South Jordan, Utah. The South Jordan Journal provides one of the best advertising channels to the residents of the City of South Jordan.

Yahoo Finance
Sep 24th, 2026
Viatris stock surges 78% in a year, outpacing S&P 500 with strong portfolio growth

Viatris Inc., a global pharmaceutical company based in Canonsburg, Pennsylvania, has significantly outperformed the S&P 500. The stock surged 8.7% over the past three months, compared to the index's 4.7% gain. Year to date, shares climbed 37.5%, whilst the S&P 500 rose 12.6%. With a market cap of $10.4 billion, Viatris operates in 165+ countries and covers more than 10 major therapeutic areas. The company sells more than 80 billion doses annually across 1,400 approved molecules. On 16 September, shares jumped 2.2% after Japan approved WAKIX for treating excessive daytime sleepiness. The company's strong performance stems from improved business momentum, solid cash generation, and progress in its higher-value product portfolio.

PR Newswire
Sep 16th, 2026
Japan approves Viatris' Wakix for narcolepsy and sleep apnoea-related daytime sleepiness

Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for WAKIX (pitolisant) to treat excessive daytime sleepiness associated with obstructive sleep apnea syndrome and narcolepsy. WAKIX is the first histamine H3 receptor antagonist/inverse agonist approved in Japan for these conditions. The treatment addresses excessive daytime sleepiness, a symptom affecting both conditions that can significantly impact daily functioning and quality of life. WAKIX is not classified as a controlled substance and has been designated an orphan drug in Japan for narcolepsy. The approval was supported by positive data from domestic Phase 3 clinical trials in Japan and international studies. WAKIX, discovered by Bioprojet and licensed to Viatris for Japan, has previously received approvals in more than 38 countries for narcolepsy.

Yahoo Finance
Aug 13th, 2026
Viatris delivers $3.8B revenue with 3.5% growth, raises outlook after strong Q2 2026

Viatris reported strong Q2 2026 results, with total revenues of $3.8 billion, representing 3.5% operational growth year-over-year. The pharmaceutical company posted adjusted EBITDA of $1.2 billion and adjusted earnings per share of $0.69. CEO Scott Smith highlighted strong commercial performance across the company's global portfolio, particularly in Greater China where investments in established brands drove meaningful growth. North America also saw solid growth from complex generics and transdermal products. The company announced US regulatory approval for Gwyn Lo last week, with a launch planned for later this year. Fast-acting meloxicam continues through FDA review, with launch preparations underway. Based on the strong quarterly performance, Viatris raised its outlook for the remainder of 2026. The results exceeded company expectations and demonstrated continued improvement in operating leverage.

Yahoo Finance
Aug 11th, 2026
Viatris beats Q2 estimates with $3.76B revenue, ups full-year guidance amid China growth and margin pressures

Viatris reported second-quarter revenue of $3.76 billion, up 4.9% year-on-year and beating analyst estimates of $3.68 billion. The medication company's non-GAAP earnings per share of $0.69 exceeded forecasts by 15%. CEO Scott Smith attributed the performance to strong commercial execution in Greater China, where investments in established brands and e-commerce drove double-digit growth. Demand for cardiovascular products and higher-margin generics in North America also contributed. The company raised its full-year adjusted EPS guidance to $2.52 at the midpoint, a 5% increase, whilst lifting revenue guidance slightly to $14.75 billion. However, operating margin fell to 0.2% from 6.5% in the prior-year quarter. Management noted supply chain disruptions and lower-margin products in emerging markets as headwinds, alongside manufacturing challenges and policy changes in China.